SR16388: A steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo

Angiogenesis

Volumn 14, Issue 1, 2011, Pages 1-16

  Chao, Wan Ru ^a   Amin, Khalid ^b   Shi, Yihui ^a   Hobbs, Peter ^a   Tanabe, Mas ^a   Tanga, Mary ^a   Jong, Ling ^a   Collins, Nathan ^a   Peters, Richard ^a   Laderoute, Keith ^a   Dinh, Dominic ^a   Yean, Dawn ^c   Hou, Carol ^a   Sato, Barbara ^a   Alt, Carsten ^a   Sambucetti, Lidia ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c StemCells   (United States)

Author keywords

Angiogenesis; Chick chorioallantoic membrane; Fibrin Z chamber model; Hypoxia inducible factor 1 ; Signal transducer and activator of transcription 3; Tube formation; Tumor xenograft; Vascular endothelial growth factor

Indexed keywords

3 HYDROXY 7ALPHA METHYL 21 [2' (N,N, DIMETHYLAMINO)ETHOXY] 19 NORPREGNA 1,3,5(10),17(20) TETRAENE; ANGIOGENESIS INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; SR 16388; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKENS; DOWN-REGULATION; ENDOTHELIAL CELLS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBRIN; G1 PHASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RATS; RATS, INBRED F344; STAT3 TRANSCRIPTION FACTOR; STEROIDS;

EID: 79952282326     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9191-z     Document Type: Article

References (85)

1. J Folkman 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 27 31 1:CAS:528:DyaK2MXjs1KnsLk%3D 10.1038/nm0195-27 7584949
2. J Folkman Y Shing 1992 Angiogenesis J Bio Chem 267 10931 10934 1:CAS:528:DyaK38XksVSmu7s%3D
3. J Folkman R Kalluri 2004 Cancer with (Pubitemid 38297724)
4. GD Yancopoulos S Davis NW Gale, et al. 2000 Vascular-specific growth factors and blood vessel formation Nature 407 242 248 1:CAS:528: DC%2BD3cXmvVSlsrY%3D 10.1038/35025215 11001067
5. LS Rosen 2005 VEGF-targeted therapy: therapeutic potential and recent advances Oncologist 10 382 391 1:CAS:528:DC%2BD2MXovVOrs78%3D 10.1634/theoncologist.10-6-382 15967832 (Pubitemid 40993566)
6. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335 1:CAS:528:DC%2BD2MXlsVChtLs%3D 10.1016/j.bbrc.2005.05.132 15961063 (Pubitemid 40848295)
7. Y Takahashi Y Kitadai CD Bucana, et al. 1995 Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon Cancer Cancer Res 55 3964 3968 1:CAS:528:DyaK2MXotV2msLg%3D 7664263
8. CA Boocock DS Charnock-Jones AM Sharkey, et al. 1995 Expression of vascular endothelial growth factor and its receptor flt and KDR in ovarian carcinoma J Natl Cancer Inst 87 7 506 516 1:CAS:528:DyaK2MXlsVequrc%3D 10.1093/jnci/87.7.506 7707437
9. G Zeng SM Taylor JR McColm, et al. 2007 Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation Blood 109 1345 1352 1:CAS:528:DC%2BD2sXjt1Cgsr4%3D 10.1182/blood-2006-07-037952 17068148 (Pubitemid 46239563)
10. S Kliche J Waltenberger 2001 VEGF receptor signaling and endothelial function IUBMB Life 52 61 66 1:CAS:528:DC%2BD38Xmt12kug%3D%3D 10.1080/15216540252774784 11795595 (Pubitemid 33769671)
11. L Claesson-Welch 2003 Signal transduction by vascular endothelial growth factor receptors Biochem Soc Trans 31 20 24 10.1042/BST0310020
12. F Shojaei N Ferrara 2007 Antiangiogensis to treat cancer and intraocular neovascular disorders Lab Invest 87 227 230 1:CAS:528:DC%2BD2sXisVeiu74%3D 10.1038/labinvest.3700526 17259997 (Pubitemid 46353946)
13. Folkman J, Kalluri R (2003) Tumor angiogenesis. In: Kufe DW, Pollock RE, Weichselbaum RR et al (eds) Cancer medicine. B.C. Decker Inc., Hamilton, pp 161-194
14. R Satchi-Fainaro R Mamluk L Wang, et al. 2005 Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin Cancer Cell 7 251 261 1:CAS:528:DC%2BD2MXivFCqu78%3D 10.1016/j.ccr.2005.02.007 15766663 (Pubitemid 40568684)
15. ZH Huang YF Fan H Xia, et al. 2003 Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice World J Gastroenterol 9 2 281 283 1:CAS:528:DC%2BD3sXhsFynu78%3D 12532448 (Pubitemid 36215804)
16. JH Huang JS Fischer T New, et al. 2004 TNP-470 promotes initial vascular sprouting in xenograft tumors Mol Cancer Ther 3 3 335 343 1:CAS:528: DC%2BD2cXitFCns7Y%3D 15026554 (Pubitemid 39193709)
17. O Benny O Fainaru A Adini, et al. 2008 An orally delivered small-molecule formulation with antiangiogenic and anticancer activity Nat Biotechnol 26 7 799 807 1:CAS:528:DC%2BD1cXot1entL8%3D 10.1038/nbt1415 18587385 (Pubitemid 351961454)
18. M Hockel P Vaupel 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 4 266 276 1:CAS:528:DC%2BD3MXhsFGjs7s%3D 10.1093/jnci/93.4.266 11181773 (Pubitemid 32219813)
19. JE Jung HS Kim CS Lee, et al. 2007 Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells Carcinogenesis 28 8 1780 1787 1:CAS:528:DC%2BD2sXpt1ehtbc%3D 10.1093/carcin/bgm130 17557905 (Pubitemid 47289042)
20. GL Semenza 2009 Regulation of cancer cell metabolism by hypoxia-induced factor-1 Semin Cancer Biol 19 12 16 1:CAS:528:DC%2BD1MXitF2hsr4%3D 10.1016/j.semcancer.2008.11.009 19114105
21. GL Semenza 2007 Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling J Cell Biochem 102 840 847 1:CAS:528:DC%2BD2sXhtlSisLzE 10.1002/jcb.21523 17891779 (Pubitemid 350036924)
22. N Simiantonaki C Jayasinghe R Michel-Schmidt, et al. 2008 Hypoxia-induced epithelial VEGFD-C/VEGFR-3 upregulation in carcinoma cell lines Int J Oncol 32 585 592 1:CAS:528:DC%2BD1cXjs1Cmur8%3D 18292935 (Pubitemid 351330464)
23. AM Byrne DJ Bouchier-Hayes JH Harmey 2005 Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J Cell Mol Med 9 4 777 794 1:CAS:528:DC%2BD2sXlvFKhtLg%3D 10.1111/j.1582-4934.2005.tb00379.x 16364190 (Pubitemid 43116546)
24. G Niu J Briggs J Deng, et al. 2008 Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells Mol Cancer Res 6 7 1099 1105 1:CAS:528:DC%2BD1cXoslCgtr4%3D 10.1158/1541-7786.MCR-07-2177 18644974
25. KS Kimbro JW Simons 2006 Hypoxia-inducible factor-1 in human breast and prostate cancer Endocr Relat Cancer 13 739 749 1:CAS:528:DC%2BD28XhtlequrzN 10.1677/erc.1.00728 16954428 (Pubitemid 44763255)
26. TM LaVallee PA Burke GM Swartz, et al. 2008 Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198 Mol Cancer Ther 7 6 1472 1482 1:CAS:528:DC%2BD1cXnsVSktL4%3D 10.1158/1535-7163.MCT- 08-0107 18566218
27. C Moser SA Lang A Mori, et al. 2008 ENMD-1198, a novel tubulin-binding agent reduces HIF-1 alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo BMC Cancer 8 206 10.1186/1471-2407-8-206 18651980
28. KAZ Siddiquee J Turkson 2008 STAT3 as a target for inducing apoptosis in solid and haematological tumors Cell Res 18 254 267 10.1038/cr.2008.18 (Pubitemid 351206162)
29. EC Brantley LB Nabors GY Gillespie, et al. 2008 Loss of protein inhibitors of activated STAT3 expression in glioblatoma multiform tumors: implications for STAT3 activation and gene expression Clin Cancer Res 14 4694 4704 1:CAS:528:DC%2BD1cXpt1ejsb8%3D 10.1158/1078-0432.CCR-08-0618 18676737
30. G Niu KL Wright M Huang, et al. 2002 Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis Oncogene 21 2000 2008 1:CAS:528:DC%2BD38XivVelur4%3D 10.1038/sj.onc.1205260 11960372 (Pubitemid 34270888)
31. Z Chen ZC Han 2008 STAT3: a critical transcription activator in angiogenesis Med Res Rev 28 2 185 200 1:CAS:528:DC%2BD1cXjsVertbk%3D 10.1002/med.20101 17457812 (Pubitemid 351281185)
32. LK Schaefer Z Ren GN Fuller, et al. 2002 Constitutive activation of STAT3α in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor 2 (VEGFR2) Oncogene 21 2058 2065 1:CAS:528:DC%2BD38XivVelurg%3D 10.1038/sj.onc.1205263 11960378 (Pubitemid 34270894)
33. M Kortylewski H Yu 2008 Role of STAT3 in suppressing anti-tumor immunity Curr Opin Immunol 20 2 228 233 1:CAS:528:DC%2BD1cXntlSktrk%3D 10.1016/j.coi.2008.03.010 18479894
34. ES Kim SY Hong HK Lee, et al. 2008 Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells Oncol Rep 20 1321 1327 1:CAS:528:DC%2BD1MXjs1Giug%3D%3D 19020709
35. AB Heimberger W Priebe 2008 Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers Recent Pat CNS Drug Discov 3 3 179 188 1:CAS:528:DC%2BD1cXhtFKms7vM 10.2174/157488908786242489 18991807
36. OA Timofeeva V Gaponenko SJ Lockett, et al. 2007 Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target ACS Chem Biol 2 12 799 809 1:CAS:528:DC%2BD2sXhsVCrs7jK 10.1021/cb700186x 18154267 (Pubitemid 351166055)
37. RP Singh K Raina G Deep, et al. 2009 Silibinin suppress growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling Clin Cancer Res 15 2 613 621 1:CAS:528: DC%2BD1MXlvFeqsw%3D%3D 10.1158/1078-0432.CCR-08-1846 19147767
38. A Tyagi RP Singh K Ramasamy, et al. 2009 Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage- associated cytokines and nuclear factor-kB and signal transducers and activators of transcription 3 Cancer Prev Res 2 1 74 83 1:CAS:528:DC%2BC3cXptFOisrw%3D 10.1158/1940-6207.CAPR-08-0095
39. H Leong PS Mathur GL Greene 2009 Green tea catechins inhibit angiogenesis through suppression of STAT3 activation Breast Cancer Res Treat 117 505 515 1:CAS:528:DC%2BD1MXhtFegur7J 10.1007/s10549-008-0196-x 18821062
40. RA Nemenoff RA Winn 2005 Role of nuclear receptors in lung tumourigenesis Eur J Cancer 41 2561 2568 1:CAS:528:DC%2BD2MXhtFyks7rP 10.1016/j.ejca.2005.08. 015 16199155 (Pubitemid 41540630)
41. B Sola JM Renoir 2006 Antiestrogenic therapies in solid cancers and multiple myeloma Curr Mol Med 6 359 368 1:CAS:528:DC%2BD28XlsVGmsLk%3D 10.2174/156652406777435408 16900659 (Pubitemid 43840603)
42. JM Hall DP McDonnell 1999 The estrogen receptor beta-osiform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens Endocrinology 140 5566 5578 1:CAS:528:DyaK1MXns12htro%3D 10.1210/en.140.12.5566 10579320 (Pubitemid 30645344)
43. HA Harris 2007 Estrogen receptor-β: recent lessons from in vivo studies Mol Endocrinol 21 1 1 13 1:CAS:528:DC%2BD2sXmsFOnsw%3D%3D 10.1210/me.2005-0459 16556737 (Pubitemid 46041687)
44. LG Horvath SM Henshall C-S Lee, et al. 2001 Frequent loss of estrogen receptor-β expression in prostate cancer Cancer Res 61 5331 5335 1:CAS:528:DC%2BD3MXlsVCiu7k%3D 11454669 (Pubitemid 32694904)
45. M Stettner S Kaulfub P Burfeind, et al. 2007 The relevance of estrogen receptor-β expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment Mol Cancer Ther 6 10 2626 2633 1:CAS:528:DC%2BD2sXhtFKltbbM 10.1158/1535-7163. MCT-07-0197 17913855 (Pubitemid 350058143)
46. O Imamov NA Lopatkin J-K Gustafsson 2004 Estrogen receptor β in prostate cancer N Engl J Med 351 26 2773 2774 10.1056/NEJM200412233512622 15616218 (Pubitemid 39665338)
47. A Pravettoni O Mornai PGV Martini, et al. 2007 Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells Mol Cell Endocrinol 263 46 54 1:CAS:528:DC%2BD28Xht1KgurzL 10.1016/j.mce.2006.08.008 17023111 (Pubitemid 44828230)
48. LP Stabile AL Davis CT Gubish, et al. 2002 Human non-small cell lung tumors and cell derived from normal lung express both estrogen receptors (alpha) and (beta) and show biological response to estrogen Cancer Res 62 7 2141 2150 1:CAS:528:DC%2BD38XivVylu7k%3D 11929836 (Pubitemid 34408463)
49. DC Marquez-Garban HW Chen MC Fishbein, et al. 2007 Estrogen receptor signaling pathways in human non-small cell lung cancer Steroids 72 135 143 1:CAS:528:DC%2BD2sXit1Kjsro%3D 10.1016/j.steroids.2006.11.019 17276470 (Pubitemid 46273500)
50. G Ali V Donati B Loggini, et al. 2008 Different estrogen receptors expression in distinct histologic subtypes of lung adenocarcinoma Human Pathol 39 1465 1473 1:CAS:528:DC%2BD1cXhtVyltbrO 10.1016/j.humpath.2008.02.011
51. BG Skov BM Fisher H Pappot 2008 Oestrogen receptor β over expression in males with non-small cell lung cancer is associated with better survival Lung Cancer 59 88 94 10.1016/j.lungcan.2007.07.025 17905466
52. Y Omoto Y Kobayashi K Nishida, et al. 2001 Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers Biochem Biophys Res Commun 285 340 347 1:CAS:528:DC%2BD3MXkvFOru7w%3D 10.1006/bbrc.2001.5158 11444848 (Pubitemid 32918076)
53. SP Treon G Teoh M Urashima, et al. 1998 Anti-estrogens induce apoptosis of multiple myeloma cells Blood 92 1749 1757 1:CAS:528:DyaK1cXls1Shs7s%3D 9716605 (Pubitemid 28406881)
54. T Otsuki O Yamada J Kurebayshi, et al. 2000 Estrogen receptors in human myeloma cells Cancer Res 60 1434 1441 1:CAS:528:DC%2BD3cXhvFWrtLc%3D 10728710 (Pubitemid 30152018)
55. B Sola JM Renoir 2007 Estrogenic or anti estrogenic therapies for multiple myeloma? Mol Cancer 6 59 10.1186/1476-4598-6-59 10.1186/1476-4598-6-59 17888187 (Pubitemid 350176268)
56. A Gagliardi DC Collins 1993 Inhibition of angiogenesis by antiestrogens Cancer Res 53 533 535 1:CAS:528:DyaK3sXitVCku78%3D 7678775 (Pubitemid 23059432)
57. DJ Lindner EC Borden 1997 Effects of tamoxifen and interferon-β or the combination on tumor-induced angiogenesis Int J Cancer 71 456 461 1:CAS:528:DyaK2sXjtleqs70%3D 10.1002/(SICI)1097-0215(19970502)71:3<456::AID- IJC25>3.0.CO;2-C 9139884 (Pubitemid 27224313)
58. Tanabe M, Peters R, Chao W-R et al (2000) Antiestrogenic steroids, and associated pharmaceutical compositions and methods of use. U.S. Patent 6,054,446 April 25 2000
59. Y Guo AA Higazi A Arakelian, et al. 2000 A peptide derived from the non-receptor-binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo FASEB 14 1400 1410 1:CAS:528:DC%2BD3cXks12jtbk%3D 10.1096/fj.14.10.1400 (Pubitemid 30439749)
60. K Amin J Li W-R Chao, et al. 2003 Dietary glycine inhibits angiogenesis during wound healing and tumor growth Cancer Biol Ther 2 2 173 178 1:CAS:528:DC%2BD3sXmvFGhsLY%3D 12750558
61. HE Ryan M Poloni W McNulty, et al. 2000 Hypoxia-inducible factor-1α is a positive factor in solid tumor growth Cancer Res 60 4010 4015 1:CAS:528:DC%2BD3cXlvFOksb8%3D 10945599 (Pubitemid 30636574)
62. BJ Murphy BG Sato TP Dalton, et al. 2005 The metal-responsive transcription factor-1 contributes to HIF-1 activation during hypoxia stress Biochem Biophys Res Commun 337 860 867 1:CAS:528:DC%2BD2MXhtFCjs7zE 10.1016/j.bbrc.2005.09.124 16216223 (Pubitemid 41446993)
63. KM Quesnelle AL Boeham JR Grandis 2007 STAT-mediated EGFR signaling in cancer J Cell Biochem 102 311 319 1:CAS:528:DC%2BD2sXhtFKjtLnF 10.1002/jcb.21475 17661350 (Pubitemid 47519405)
64. SP Gao KG Mark K Leslie, et al. 2007 Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas J Clin Invest 117 12 3846 3856 1:CAS:528:DC%2BD2sXhsValsL%2FO 10.1172/JCI31871 18060032 (Pubitemid 350224094)
65. C Gridelli MA Bareschino C Schettino, et al. 2007 Erlotinib in non-small cell lung cancer treatment: current status and future development Oncologist 12 840 849 1:CAS:528:DC%2BD2sXpslerur8%3D 10.1634/theoncologist.12-7-840 17673615 (Pubitemid 47328227)
66. JM Renoir C Bouclier A Seguin, et al. 2008 Antiestrogen-mediated cell cycle arrest and apoptosis induction in breast and multiple myeloma cells J Mol Endocrinol 40 101 112 1:CAS:528:DC%2BD1cXltlert7Y%3D 10.1677/JME-07-0143 18316469 (Pubitemid 351586820)
67. DM Lonard CL Smith 2002 Molecular perspectives on selective estrogen receptor modulators (SERM): progress in understanding their tissue-specific agonist and antagonist actions Steroids 67 15024 10.1016/S0039-128X(01)00133-7 (Pubitemid 33112000)
68. AU Buzadar 2005 TAS-108: a novel steroidal antiestrogen Clin Cancer Res 11 906s 908s
69. Y Kumagai T Fujita M Ozaki, et al. 2009 Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-estrogen, in healthy post menopausal Japanese women: a phase I single oral dose study Basic Clin Pharmacol Toxicol 104 352 359 1:CAS:528:DC%2BD1MXnt1Cltrk%3D 10.1111/j.1742-7843.2008.00373.x 19175362
70. SJ Eeullman JM Calaoagan BG Sato, et al. 2010 A novel steroidal inhibitor of estrogen-related receptor alpha (ERR-alpha) Biochem Pharmacol 80 819 826 10.1016/j.bcp.2010.05.024
71. V Giguere 2008 Transcriptional control of energy homeostasis by the estrogen-related receptors Endocrine Rev 29 677 696 1:CAS:528:DC%2BD1cXhtlWrurzI 10.1210/er.2008-0017
72. AM Tremblay V Giguere 2007 The NR3B subgroup: an overview Nucl Recept Signal 5 e009 18174917
73. A Ao H Wang S Kamarajugadda, et al. 2008 Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors Proc Natl Acad Sci USA 105 7821 7826 1:CAS:528:DC%2BD1cXntF2qsLs%3D 10.1073/pnas.0711677105 18509053 (Pubitemid 351872722)
74. P Mak I Leav B Pursell, et al. 2010 ER-β impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implication for Gleason grading Cancer Cell 17 4 319 332 1:CAS:528:DC%2BC3cXmsF2msLs%3D 10.1016/j.ccr.2010.02.030 20385358
75. AL Bookout Y Jeong M Downes, et al. 2006 Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network Cell 126 789 799 1:CAS:528:DC%2BD28Xpt1akurs%3D 10.1016/j.cell.2006.06.049 16923397 (Pubitemid 44233630)
76. JS Lai LG Brown LD True 2004 Metastases of prostate cancer express estrogen receptor = beta Urology 64 4 814 820 10.1016/j.urology.2004.05.036 15491740 (Pubitemid 39446081)
77. X Zhu I Leave YK Leung, et al. 2004 Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis Am J Pathol 164 6 2003 2012 1:CAS:528:DC%2BD2cXltFyms7k%3D 10.1016/S0002-9440(10)63760-1 15161636 (Pubitemid 38669349)
78. K Kuba K Matsumoto K Date 2000 HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice Cancer Res 60 6737 6743 1:CAS:528: DC%2BD3cXosl2it7w%3D 11118060
79. R Buettner LB Mora R Jove 2002 Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention Clin Cancer Res 8 945 954 1:CAS:528:DC%2BD38XjsF2lsb4%3D 11948098 (Pubitemid 35177340)
80. J Bromberg JE Darnell Jr 2000 The role of STATs in transcriptional control and their impact on cellular function Oncogene 19 2468 2473 1:CAS:528:DC%2BD3cXktVGhsb4%3D 10.1038/sj.onc.1203476 10851045 (Pubitemid 30339202)
81. M Bartoli D Plantt T Lemtalsi, et al. 2003 VEGF differentially activates STAT3 in microvascular endothelial cells FASEB J 17 1562 1564 1:CAS:528:DC%2BD3sXmtVKnsb4%3D 12824281
82. S Alas B Bonavida 2003 Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin Cancer Res 9 316 326 1:CAS:528:DC%2BD3sXnt1Ortw%3D%3D 12538484 (Pubitemid 36109748)
83. SH Chen DA Murphy W Lassoued, et al. 2008 Activated STAT3 is a mediator and biomarker of VEGF endothelial activation Cancer Biol Ther 7 12 1994 2003 1:CAS:528:DC%2BD1MXit1GltLc%3D 10.4161/cbt.7.12.6967 18981713
84. Y Yahata Y Shirakata S Tokumaru, et al. 2003 Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation J Biol Chem 278 40026 40031 1:CAS:528:DC%2BD3sXnvFamsL8%3D 10.1074/jbc.M301866200 12874294 (Pubitemid 37248568)
85. Q Xu J Briggs S Park, et al. 2005 Targeting STAT3 blocks both HIF and VEGF expression induced by multiple oncogenic growth signaling pathways Oncogene 24 5552 5560 1:CAS:528:DC%2BD2MXovVOns7c%3D 10.1038/sj.onc.1208719 16007214 (Pubitemid 43119350)